Literature DB >> 24472483

Assessment of cervical cancer screening policy in Korea for women over age 65.

Sanghoon Lee1, Hyun Tae Park1, Jin Hwa Hong1, Jae Yun Song2, Jae Kwan Lee1, Nak Woo Lee1, Tak Kim1, Kyu Wan Lee1.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the efficacy of cervical cancer screening (CCS) in Korean women over 65 years of age and to determine the age at which CCS becomes inefficacious, so that providers and policy makers can be more informed about when to stop screening.
MATERIALS AND METHODS: The data of 999 women, who underwent CCS followed by colposcopy at the Korea University hospital from January 2007 to May 2012, were retrospectively evaluated. Age groups were classified as <21 (n=11), 21-29 (n=128), 30-65 (n=768), and >65 (n=92). To evaluate the value of CCS in women older than 65, age groups were simply divided into ≤ 65 or >65. Participants were also categorized into five strata of age groups (≤ 55 vs. >55, ≤ 60 vs. >60, ≤ 65 vs. >65, ≤ 70 vs. >70, and ≤ 75 vs. >75) that were compared to the sample to assess a cutoff-age at which to cease screening based on decreased efficacy.
RESULTS: The mean age was 45.5 ± 13.7 (range 14-80). There were no differences in the pathologic results for cervical intraepithelial neoplasia (CIN) values of < CIN2 vs. ≥ CIN2, or ≤ CIN3 vs. cancer among the groups. There was a significantly higher incidence of cancer compared with ≤ CIN3 in women aged >65 (13.0%) vs. ≤ 65 (6.6%), (p=0.037). To assess the cervical cancer incidence (CCI) from the larger number of cases by age, a prediction formula was calculated from a national dataset. CCI (per 100,000) continuously increased by age even for those in their 90 s.
CONCLUSION: CCS is still necessary in Korean women older than 65 since there is a substantial CCI rate occurring in these women. It is time to consider new guidelines that include the appropriate age and conditions for discontinuing screening.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  Age; Cervical cancer; Guideline; Policy; Screening

Mesh:

Year:  2013        PMID: 24472483     DOI: 10.1016/j.jgo.2013.03.001

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  4 in total

1.  Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma.

Authors:  Jinyu Li; Maia Chanrion; Eric Sawey; Tim Wang; Edward Chow; Aaron Tward; Yi Su; Wen Xue; Robert Lucito; Lars Zender; Scott W Lowe; J Michael Bishop; Scott Powers
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

2.  Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China.

Authors:  Qian Zhang; Minyi Zhao; Di Cao; Xing Wei; Li Wang; Yang Li; Ting Yang; Juan Zhao; Meili Pei; Hongran Jia; Siyu Cao; Shimin Quan; Xiaofeng Yang
Journal:  J Med Virol       Date:  2017-10-17       Impact factor: 2.327

3.  Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009-2014.

Authors:  Seung Hyuk Shim; Hyeongsu Kim; In Sook Sohn; Han Sung Hwang; Han Sung Kwon; Sun Joo Lee; Ji Young Lee; Soo Nyung Kim; Kunsei Lee; Sounghoon Chang
Journal:  J Gynecol Oncol       Date:  2017-05-26       Impact factor: 4.401

4.  A prospective pilot evaluation of vaginal and urine self-sampling for the Roche cobas 4800 HPV test for cervical cancer screening.

Authors:  Sang-Hyun Hwang; Hye Young Shin; Dong Ock Lee; Na Young Sung; Bomyee Lee; Do-Hoon Lee; Jae Kwan Jun
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.